AI-powered
Meningicoccal vaccine
Study on the Efficacy of an Investigational Treatment for Migraine Prevention
Recruiting
42 days - 89 days
All
Phase
3
1660 participants needed
1 Location
Study Overview
Test
Updated on
06 Feb 2025.
Study ID: NCT03547271
- Who can participate: Adults aged 18-65 who have a history of migraines for at least one year and experience four or more migraine days per month are eligible to participate.
- Study details: Participants will receive either the investigational treatment or a placebo and will be monitored for changes in migraine frequency.